Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib.

Cancer discovery - 1 Apr 2020

Abstract excerpt

In a phase Ib trial, osimertinib plus savolitinib showed efficacy in non-small cell lung cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Pyrazines

Share to Triazines

Source

Identifiers

PMID: 32060054
DOI: 10.1158/2159-8290.CD-RW2020-025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib.PMID 32060054Read ↗

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).Semantic proximity Read ↗

Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.Semantic proximity Read ↗

Savolitinib for non-small cell lung cancer.Semantic proximity Read ↗

Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.Semantic proximity Read ↗

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.Semantic proximity Read ↗

Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.Semantic proximity Read ↗

Savolitinib: A Promising Targeting Agent for CancerSemantic proximity Read ↗

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.Semantic proximity Read ↗

Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.Semantic proximity Read ↗

Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.